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of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA; 5Department of Medicine, Washington University School of
Medicine, St. Louis, Missouri, USA; 6Department of Psychological Sciences, University of Missouri-St. Louis, St. Louis, Missouri, USA;
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The last quarter century witnessed signiﬁcant population
growth, aging, and major changes in epidemiologic trends,
which may have shaped the state of chronic kidney disease
(CKD) epidemiology. Here, we used the Global Burden of
Disease study data and methodologies to describe the
change in burden of CKD from 1990 to 2016 involving
incidence, prevalence, death, and disability-adjusted-life-
years (DALYs). Globally, the incidence of CKD increased by
89% to 21,328,972 (uncertainty interval 19,100,079–
23,599,380), prevalence increased by 87% to 275,929,799
(uncertainty interval 252,442,316–300,414,224), death due
to CKD increased by 98% to 1,186,561 (uncertainty interval
1,150,743–1,236,564), and DALYs increased by 62% to
35,032,384 (uncertainty interval 32,622,073–37,954,350).
Measures of burden varied substantially by level of
development and geography. Decomposition analyses
showed that the increase in CKD DALYs was driven by
population growth and aging. Globally and in most Global
Burden of Disease study regions, age-standardized DALY
rates decreased, except in High-income North America,
Central Latin America, Oceania, Southern Sub-Saharan
Africa, and Central Asia, where the increased burden of CKD
due to diabetes and to a lesser extent CKD due to
hypertension and other causes outpaced burden expected
by demographic expansion. More of the CKD burden (63%)
was in low and lower-middle-income countries. There was
an inverse relationship between age-standardized CKD
DALY rate and health care access and quality of care.
Frontier analyses showed signiﬁcant opportunities for
improvement at all levels of the development spectrum.
Thus, the global toll of CKD is signiﬁcant, rising, and
unevenly distributed; it is primarily driven by demographic
expansion and in some regions a signiﬁcant tide of
diabetes. Opportunities exist to reduce CKD burden at all
levels of development.
Kidney International (2018) 94, 567–581; https://doi.org/10.1016/
j.kint.2018.04.011
KEYWORDS: age; CKD burden; chronic kidney disease; DALYs; diabetes;
death; epidemiology; global health; glomerulonephritis; hypertension;
incidence; prevalence; population
Published by Elsevier, Inc., on behalf of the International Society of
Nephrology. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
T he last quarter century witnessed signiﬁcant globalpopulation growth, aging, and an accelerated pace ofepidemiologic transition, with reduced mortality from
communicable diseases and increased burden of non-
communicable diseases.1,2 Globally, the burden of diabetes
and hypertension considered as the 2 leading drivers of
chronic kidney disease (CKD) has increased signiﬁcantly over
the past several decades. The number of adults living with
diabetes quadrupled between 1980 and 2014, increasing from
108 million in 1980 to 422 million adults in 2014.3 The
number of adults with elevated blood pressure increased from
594 million in 1975 to 1.13 billion in 2015.4 The increase in
burden of diabetes and elevated blood pressure occurred at a
much faster rate in low- and middle-income countries than in
high-income countries.3–6
The global forces of demographic expansion and epidemi-
ologic transition have shaped the epidemiology of non-
communicable diseases including diabetes and hypertension
and very likely has shaped the state of CKD epidemiology.
However, a detailed quantitative analysis of the global, regional,
and national burden of CKD over the past 25 years is not
available. In this work, we used the Global Burden of Disease
(GBD) data from 1990 to 2016 to (i) describe the state of CKD
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epidemiology at the global, regional, and national level; (ii)
examine how demographic and epidemiologic drivers shaped
the change in burden of CKD over this period; and (iii) char-
acterize the relationship between burden of CKD andmeasures
of health and economic prosperity in any given country.
RESULTS
GBD terms and deﬁnitions used in this work are provided in
Table 1. Demographics, Sociodemographic Index (SDI), and
Healthcare Access and Quality (HAQ) parameters at the global
level and by SDI quintile are presented in Table 2. The global
incidence of CKDwas 11,299,557.27 (95% uncertainty interval
[UI]¼ 10,220,333.36–12,357,374.38) in 1990, and increased to
21,328,971.86 (UI ¼ 19,100,079.20–23,599,380.24) in 2016—
representing an 88.76% increase in incidence over the last 27
years. CKD incidence rate per 100,000 population increased
from 214.63 (UI ¼ 194.13–234.72) in 1990 to 288.53 (UI ¼
258.38–319.24) in 2016. Age-standardized incident rate per
100,000 population increased from 299.06 (UI ¼ 269.36–
329.00) to 310.13 (UI ¼ 275.51–343.70) (Table 3 and
Supplementary Figure S1A). Age-standardized incident rate
increased for CKD due to diabetes, glomerulonephritis, and
CKD due to other causes; it decreased for CKD due to hyper-
tension (Table 3 and Supplementary Figure S1B).
The overall global prevalence of CKD increased from
147,598,152.80 (UI¼ 135,827,679.51–160,280,895.47) in 1990
to 275,929,799.20 (UI ¼ 252,442,315.84–300,414,224.26) in
2016; representing an 86.95% increase in prevalence over the
last 27 years. Prevalence rate per 100,000 population increased
from 2803.54 (UI ¼ 2579.97–3044.44) to 3732.67 (UI ¼
3414.94–4063.89). Age-standardized prevalence rate increased
from 4040.95 (UI ¼ 3710.83–4382.80) to 4056.54 (UI ¼
3706.70–4414.26) (Table 4 and Supplementary Figure S2A).
Age-standardized prevalence rate increased for CKD due to
diabetes, and decreased for CKD due to hypertension,
glomerulonephritis, and other causes (Table 4 and
Supplementary Figure S2B).
Global death due to CKD increased from 599,200.30 (UI ¼
577,653.17–650,084.02) in 1990 to 1,186,560.90 (UI ¼
1,150,743.14–1,236,564.41) in 2016, representing a 98.02%
increase in death due to CKD over the last 27 years. From 1990
to 2016, CKD death per 100,000 population increased from
11.38 (UI ¼ 10.97–12.35) to 16.05 (UI ¼ 15.57–16.73); age-
standardized death rate increased from 17.48 (UI ¼ 16.89–
18.98) to 18.25 (UI ¼ 17.73–18.97) (Table 5 and
Supplementary Figure S3A). Age-standardized death rate
increased for CKD due to diabetes and hypertension, decreased
for CKD due to glomerulonephritis, and remained relatively
unchanged for CKD due to other causes (Table 5 and
Supplementary Figure S3B).
Global disability-adjusted life-years (DALYs) were
21,597,163.60 (UI ¼ 20,093,986.99–23,354864.85) in 1990,
and increased to 35,032,384.43 (UI ¼ 32,622,072.69–
37,954,350.03) in 2016; representing a 62.21% increase in
DALYs over the last 27 years. DALY rates per 100,000 popu-
lation increased from 410.23 (UI ¼ 381.67–443.61) to 473.90
(UI ¼ 441.30–513.43). Age-standardized DALY rates
decreased from 521.44 (UI ¼ 484.58–565.29) to 500.12 (UI ¼
465.54–541.43) in 2016 (Table 6 and Supplementary
Figure S4A). Age-standardized DALY rates by cause revealed
an increase in CKD DALYs attributable to diabetes and to a
lesser extent hypertension, and decrease in CKD DALYs
Table 1 | Terms and deﬁnitions
Age-standardized rate: Rate per 100,000 population following
standardization to the global age structure. The difference between
age-standardized rates across geographies and over time is
independent of population size and age structure.
Decomposition: The analytic approach to identify the additive
contribution of the effect of the differences in factors in 2 populations
to the difference in their overall value. Decomposition of chronic kidney
disease (CKD) DALYs by age structure, population growth, and
epidemiologic changes allows the quantiﬁcation of contribution of each
of these factors to the overall effect. Similarly, decomposition of CKD
DALYs by the 4 causes of CKD allows the quantiﬁcation of the
contribution of each cause to the overall CKD DALYs.
Disability-adjusted life-years (DALYs): A measure that quantitates the
overall burden of disease in terms of years of healthy life lost due to the
disease. It represents the sum of years lost due to premature death and
years living with disability due to the disease. The years of living with
disability are weighted in proportion to the severity of the underlying
disease.
Frontier analysis: The analytic approach used to identify the lowest
potentially achievable burden of CKD on the basis of development
status, as measured by the Sociodemographic Index (SDI). The frontier
delineates the countries or territories with leading performance (at the
frontier pushing the envelope) that have the lowest CKD burden for
their SDI. Distance from the frontier is termed “effective difference” and
represents the gap between the observed burden and the potentially
achievable burden of disease in a country or territory given their SDI;
this gap could be potentially reduced or eliminated based on the
country or territory’s sociodemographic resources. For example, if a
country or territory falls well below the frontier value given its SDI, this
observation suggests unrealized opportunity for reduction (or
improvement) in CKD DALYs that should be possible based on the
country or territory’s place on the development spectrum.
Global Burden of Diseases, Injuries, and Risk Factors Study (GBD): A
global research study group headquartered at the Institute of Health
Metrics and Evaluation at the University of Washington in Seattle. It
comprises more than 3000 international collaborators from more than
130 countries and aims to quantitate the burden of disease, disability,
and death from 333 diseases and injuries, and 88 risk factors in 195
countries and territories, by age and sex, from 1990 to the present,
allowing comparisons over time, across age groups, and among
populations. The GBD study is funded by the Bill and Melinda Gates
Foundation.
Healthcare Quality and Access (HAQ) index: A novel summary measure
on a scale of 0 (worst) to 100 (best) that was recently developed by the
GBD study. It is based on risk standardized death rates of 32 GBD causes
that are considered amenable to personal health care. It provides a
single interpretable measure that facilitates comparable assessment of
personal health care access and quality across 195 countries and
territories, over time, and along the development spectrum.
Sociodemographic Index (SDI): A summary measure that quantitates a
country or territory’s level of a sociodemographic development. It is
interpretable across geographies and over time. SDI is expressed on a
scale of 0 to 1 and is the composite average of the rankings of the
incomes per capita, average educational attainment, and total fertility
rates of all areas in the GBD study. Zero represents the lowest income
per capita, lowest educational attainment, and highest total fertility rate
observed across all GBD geographies from 1970 to 2016, and 1
represents the highest income per capita, highest educational
attainment, and lowest total fertility rate.
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attributable to glomerulonephritis and other causes (Table 6
and Supplementary Figure S4B). Estimates for incidence,
prevalence, death and DALYs due to CKD as absolute values,
rates per 100,000 population, age-standardized rates per
100,000 population, and by causes at the regional and na-
tional level are presented in Supplementary Table S2A–D.
Prevalence of CKD by age and sociodemographic
development in 2016
Worldwide raw prevalence and age-standardized prevalence
rate of CKD in 2016 are shown in Figure 1a and b, respectively.
The prevalence rate of CKD per 100,000 population by age
group showed an earlier rise for low-SDI countries; countries
in the highest SDI quintile exhibited a later and much steeper
rise, with the prevalence rate exceeding that of any SDI quintile
in age groups>90 (Figure 2). To gain a better understanding of
the age distribution of people with CKD globally and by SDI
quintile, an age proﬁle of CKD was constructed. We observed
differences in percent CKD by age group across the SDI spec-
trum; the differences appeared graded across the development
spectrum and were most manifest between highest and lowest
SDI quintile. There was a greater percentage of CKD earlier in
life (in adolescent years and early adulthood), and an earlier
peak (age group 60–64) in low-SDI countries than in high-SDI
countries. In high-SDI countries, the increase started to man-
ifest in third decade of life, and achieved a higher and later peak
(age group 75–79). All SDI quintiles exhibited a sharp decline
in percent CKD following the peak (Supplementary
Figure S5A). The age distribution of death due to CKD
exhibited a similar pattern in that more death due to CKD
occurred in younger age groups in low-SDI countries than in
high-SDI countries (Supplementary Figure S5B).
Drivers of CKD epidemiology: population growth, aging, and
epidemiologic changes
To examine to what extent the forces of population growth,
aging, and epidemiologic changes shaped CKD epidemiology
over the past 27 years, we developed a decomposition analysis
of raw DALYs by population, age structure, and age and pop-
ulation standardized morbidity and mortality rates (which we
are referring to here as epidemiologic changes). Overall, there
was a signiﬁcant increase in CKD DALYs globally and in each
SDI quintile, but it was most pronounced in middle and low-
middle SDI quintiles, which exhibited the largest increase in
overall DALYs in the past 27 years (Figure 3). Globally, popu-
lation growth followed by aging of the world population
contributed 69.80% and 42.86%, respectively, to the increased
burden of CKD DALYs between 1990 and 2016
(Supplementary Figure S6A). The contribution of aging to
overall DALYs was most pronounced in the high-SDI quintile
(70.09%), and decreased where it was 64.00% in the high-
middle–, 66.27% in the middle, 40.24% in the low-middle–,
and nearly vanished in the low-SDI quintile (1.60%). Most of
the increase in CKDDALYswas driven by population growth in
low-middle– (100.42%) and low-SDI quintiles (112.32%); the
relative contribution of population growth to increase in CKD
DALYs was smaller (32.71%) in high-SDI countries. The
epidemiologic changes that capture the underlying change in
age and population-adjusted CKD morbidity and mortality
rates over the past 27 years have decreased globally, and the
decrease was least pronounced in high- and low-SDI quintiles,
and was more evident in low-middle–, middle-, and high-
middle– SDI quintiles (Figure 3, Supplementary Figure S6A,
Table 7). Decomposition analysis in GBD regions revealed
substantial heterogeneity in demographic and epidemiologic
trends. Aging and population growth were major drivers of
change in CKD DALYs in most GBD regions (Supplementary
Table S3). Most notably, whereas most GBD regions exhibi-
ted a decrease in underlying age and population-adjusted CKD
mortality and morbidity rates (epidemiologic changes)—a
trend also seen at the global level and in each SDI level—there
were several GBD regions that exhibited a remarkable deviation
from this trend and showed an increase in epidemiologic
changes, including Central Asia, High-income North America,
Central Latin America, Southern Sub-Saharan Africa, and
Oceania, which contributed 37.27%, 35.06%, 31.71%, 23.17%,
Table 2 | Demographics, SDI, and HAQ parameters at the global level and by SDI quintile
Global High SDIa High-middle SDIa Middle SDIa Low-middle SDIa Low SDIa
Populationb 7392.28 1025.59 1164.63 2299.84 2129.75 767.91
Sex (%)b
Male 3725.91 (50.40) 503.28 (49.07) 584.75 (50.21) 1165.24 (50.67) 1084.60 (50.93) 385.80 (50.24)
Female 3666.38 (49.60) 522.32 (50.93) 579.88 (49.79) 1134.60 (49.33) 1045.14 (49.07) 382.11 (49.76)
Age category (%)b
< 5 631.97 (8.55) 53.79 (5.24) 72.83 (6.25) 159.01 (6.91) 223.08 (10.47) 122.92 (16.01)
5-14 1253.20 (16.95) 111.60 (10.88) 138.94 (11.93) 347.71 (15.12) 446.00 (20.94) 208.25 (27.12)
15-49 3819.18 (51.66) 467.59 (45.59) 627.67 (53.89) 1240.26 (53.93) 1122.24 (52.69) 359.22 (46.78)
50-69 1283.64 (17.36) 262.81 (25.63) 246.62 (21.18) 438.71 (19.08) 271.38 (12.74) 63.13 (8.22)
>69 404.29 (5.47) 129.80 (12.66) 78.58 (6.75) 114.16 (4.96) 67.04 (3.15) 14.39 (1.87)
SDI (IQR)c 0.70 (0.51–0.82) 0.88 (0.87–0.90) 0.79 (0.76–0.82) 0.70 (0.67–0.73) 0.56 (0.51–0.59) 0.35 (0.31–0.43)
HAQ (IQR)c 63.40 (49.60–76.60) 86.40 (81.40–89.00) 71.80 (65.70–79.00) 63.15 (58.10–2.80) 51.85 (48.70–60.10) 43.00 (38.80–45.60)
GBD, Global Burden of Disease study; HAQ, Healthcare Access and Quality index; IQR, interquartile range; SDI, Sociodemographic Index.
All values were estimated based on GBD 2016 except for HAQ, which was estimated using GBD 2015.
aLow SDI: SDI < 0.46; low-middle SDI: 0.46–0.64; middle SDI: 0.65–0.74; high-middle SDI: 0.75–0.85; high SDI: SDI > 0.85.
bNumber presented in millions.
cMedian and IQR at country and territory level.
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and 14.31% to the increased DALYs in those GBD regions,
respectively (Supplementary Figure S6B and Supplementary
Table S3). Further analyses of those regions with increased
age and population-adjusted CKD mortality and morbidity
rates showed that the burden of CKD due to diabetes, and to a
lesser extent CKD due to hypertension and to other causes,
outpaced the burden that would be expected by demographic
factors, including population growth and aging
(Supplementary Figure S7A–E). In those GBD regions burden
of CKD due to diabetes and hypertension manifested much
earlier in life (in younger age groups), and was much higher
than expected based on demographic factors in each age group
(Supplementary Figure S7A–E). Decomposition analyses by
population growth, aging, and epidemiologic changes are
presented in Table 7 at the global and SDI level and in
Supplementary Table S3 at the regional and national level.
Decomposition analysis by cause of CKD
We developed decomposition analyses by the 4 causes of CKD
(diabetes, hypertension, glomerulonephritis, and other
causes); these analyses were not age- and population-
standardized. From 1990 to 2016, diabetes followed by hy-
pertensionwere the leading drivers of increasedDALYs globally
and in each SDI quintile (Figure 4). Globally, CKD due to
diabetes and CKD due to hypertension contributed 50.62%
and 23.26% of the overall increase in CKDDALYs, respectively.
The contribution of diabetes to the change of overall DALYs in
each SDI quintile was lowest in the low-SDI group (33.80%)
and increased in a graded fashion across the SDI spectrum,
where it was highest in the high-SDI quintile (57.23%)
(Supplementary Figure S8A and Table 7). A similar but less
dramatic picture was evident for hypertension as a driver of
change in overall CKD burden, contributing 15.31% and
23.71% of change in CKD DALYs in low- and high-SDI
quintiles, respectively. In GBD regions, diabetes was the lead-
ing driver of change in CKD DALYs (Supplementary
Figure S8B), but its relative contribution varied greatly
among geographies: it was high and exceeded 50% in Central
Europe (225.17%), Australasia (88.22%), East Asia (70.88%),
Southeast Asia (66.32%), High-income North America
(60.33%), High-income Asia Paciﬁc (59.58%), and Oceania
(57.14%), and it was least pronounced in the 4 corners of Sub-
Saharan Africa (27.88%). There was also variability in the
contribution of hypertension to change in CKD DALYs: it was
high in Central Europe (213.19%), East Asia (58.01%), West-
ern Europe (29.67%), and Southeast Asia (29.24%) and lowest
in Eastern Europe (12.88%), Central Latin America (12.64%),
and Central Asia (5.22%). Decomposition analyses by cause of
CKD are provided in Table 7 at the global and SDI level and in
Supplementary Table S3 at the regional and national level.
CKD DALYs and sociodemographic development
An analysis of population-weighted age-standardized DALY
rates by World Bank Income classiﬁcation showed that
burden of CKD is much more pronounced in low- and lower-
middle–income countries (Supplementary Figure S9). ThereTa
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Table 4 | Number, rate, age-standardized rate for overall CKD prevalence and by cause of CKD in 2016 and percentage change from 1990 globally and by SDI quintile
Location
Prevalence number
Prevalence rate per 100,000
persons Age-standardized prevalence rate per 100,000 persons
Number (UIa)
Percentage
change
from 1990 Rate (UIa)
Percentage
change
from 1990
Overall Due to diabetes Due to hypertension Due to glomerulonephritis Due to other causes
Number (UIa)
Percentage
change
from 1990 Rate (UIa)
Percentage
change
from 1990
(% attributed
to overall
rateb) Rate (UIa)
Percentage
change
from 1990
(% attributed
to overall
rateb) Rate (UIa)
Percentage
change
from 1990
(% attributed
to overall
rateb) Rate (UIa)
Percentage
change
from 1990
(% attributed
to overall
rateb)
Global 275,929,799.24
(252,442,315.84–
300,414,224.26)
86.95% 3732.67
(3414.94–4063.89)
33.14% 4056.54
(3706.70–4414.26)
0.39% 1690.73
(1487.36–1911.57)
5.87%
(41.68%)
744.10
(655.16–828.76)
–2.58%
(18.34%)
735.69
(644.72–823.81)
–5.04%
(18.14%)
886.03
(765.01–1,010.49)
–2.14%
(21.84%)
High SDIc 54,401,342.48
(49,090,889.58–
59,373,868.12)
57.10% 5304.38
(4786.58–5789.22)
35.78% 3130.33
(2838.65–3413.33)
–4.92% 1521.03
(1349.26–1707.14)
3.46%
(48.59%)
448.42
(389.23–502.65)
–13.54%
(14.33%)
490.48
(422.73–555.20)
–14.05%
(15.67%)
670.40
(572.29–776.90)
–8.51%
(21.42%)
High-middle
SDIc
50,978,711.10
(46,566,021.84–
55,646,977.83)
73.34% 4377.25
(3998.35–4778.08)
31.34% 3983.00
(3628.60–4347.50)
–1.51% 1527.36
(1363.04–1701.65)
12.60%
(38.35%)
789.57
(701.97–874.35)
–10.27%
(19.82%)
727.49
(649.01–807.93)
–13.16%
(18.26%)
938.57
(827.40–1,049.47)
–3.25%
(23.56%)
Middle SDIc 74,076,729.20
(67,564,941.57–
81,133,648.25)
102.07% 3220.95
(2937.81–3527.80)
56.55% 3458.33
(3153.88–3771.98)
0.48% 1540.27
(1348.79–1748.90)
1.55%
(44.54%)
690.17
(602.61–774.10)
0.81%
(19.96%)
635.23
(551.86–716.98)
-2.03%
(18.37%)
592.66
(501.79–683.37)
0.10%
(17.14%)
Low-middle
SDIc
71,084,491.91
(64,727,778.82 -
78,070,122.44)
102.82% 3337.70
(3039.23–3665.70)
27.97% 4994.12
(4533.83–5470.63)
0.80% 1970.47
(1692.55–2269.92)
6.84%
(39.46%)
897.72
(785.61–1013.32)
–2.57%
(17.98%)
941.33
(821.16–1063.35)
–2.81%
(18.85%)
1184.59
(1004.46–1369.99)
–2.94%
(23.72%)
Low SDIc 26,350,737.28
(23,767,164.74 -
29,106,098.64)
119.51% 3431.48
(3095.04–3790.29)
4.94% 7409.73
(6690.19–8173.08)
3.75% 2523.60
(2143.31–2947.70)
7.50%
(34.06%)
1503.26
(1301.51–1709.51)
1.93%
(20.29%)
1490.57
(1292.00–1687.99)
1.39%
(20.12%)
1892.30
(1581.07–2203.11)
2.32%
(25.54%)
CKD, chronic kidney disease; SDI, Sociodemographic Index.
aUI is the uncertainty interval, which reﬂects the certainty of an estimate based on data availability, study size, and consistency across data sources.
bPercentage attributed to overall rate is the proportion of overall age-standardized rate change attributed by each of the following 4 causes: diabetes, hypertension, glomerulonephritis, and other causes.
cLow SDI: SDI < 0.46; low-middle SDI: 0.46–0.64; middle SDI: 0.65–0.74; high-middle SDI: 0.75–0.85; high SDI: SDI > 0.85.
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Table 5 | Number, rate, and age-standardized rate for overall CKD death and by cause of CKD in 2016 and percentage change from 1990 globally and by SDI quintile
Location
Death number
Death rate per 100,000
persons Age-standardized death rate per 100,000 persons
Number (UIa)
Percentage
change
from 1990 Rate (UIa)
Percentage
change
from 1990
Overall Due to diabetes Due to hypertension
Due to
glomerulonephritis Due to other causes
Number (UIa)
Percentage
change
from 1990 Rate (UIa)
Percentage
change
from 1990
(% attributed
to overall
rateb) Rate (UIa)
Percentage
change
from 1990
(% attributed
to overall
rateb) Rate (UIa)
Percentage
change
from 1990
(% attributed
to overall
rateb) Rate (UIa)
Percentage
change
from 1990
(% attributed
to overall
rateb)
Global 1,186,560.90
(1,150,743.14–1,236,564.41)
98.02% 16.05
(15.57–16.73)
41.03% 18.25
(17.73–18.97)
4.39% 7.60
(6.88–8.27)
9.47%
(41.66%)
4.81
(4.29–5.37)
7.33%
(26.36%)
2.23
(1.97–2.52)
–7.46%
(12.24%)
3.60
(3.17–4.08)
–1.08%
(19.75%)
High SDIc 227,605.95
(221,469.92–233,472.20)
95.78% 22.19
(21.59–22.76)
69.21% 11.24
(10.95–11.52)
1.72% 5.06
(4.66–5.47)
9.16%
(45.03%)
2.67
(2.33–3.04)
10.69%
(23.72%)
1.19
(1.06–1.34)
–24.26%
(10.64%)
2.32
(2.02– 2.63)
–4.51%
(20.61%)
High-middle SDIc 143,537.36
(137,405.42–150,442.27)
78.56% 12.32
(11.80–12.92)
35.29% 11.68
(11.19–12.23)
-1.38% 4.49
(4.10–4.91)
6.63%
(38.44%)
3.04
(2.74–3.37)
11.06%
(26.03%)
1.67
(1.49–1.88)
–22.84%
(14.31%)
2.48
(2.21–2.77)
–9.20%
(21.21%)
Middle SDIc 456,587.39
(427,337.70–469,749.92)
111.97% 19.85
(18.58–20.43)
64.22% 23.64
(22.09–24.31)
-0.16% 10.20
(9.04–11.14)
1.92%
(43.15%)
7.06
(6.25–7.87)
–5.16%
(29.88%)
2.72
(2.36–3.13)
4.67%
(11.50%)
3.66
(3.14–4.17)
0.93%
(15.46%)
Low-middle SDIc 293,545.90
(276,884.41–332,196.76)
87.14% 13.78
(13.00–15.60)
18.08% 23.55
(22.17–26.68)
-2.37% 9.36
(8.20–10.77)
2.72%
(39.73%)
6.30
(5.56–7.25)
–2.62%
(26.76%)
2.57
(2.22–3.04)
–9.19%
(10.93%)
5.32
(4.50–6.41)
–6.81%
(22.58%)
Low SDIc 64,442.22
(59,084.54–70,450.52)
115.14% 8.39
(7.69–9.17)
2.85% 21.39
(19.52–23.59)
8.66% 7.48
(6.33–8.61)
17.90%
(34.99%)
5.34
(4.57– 6.16)
9.16%
(24.95%)
3.28
(2.76–3.93)
–3.76%
(15.35%)
5.28
(4.48–6.26)
4.95%
(24.71%)
CKD, chronic kidney disease; SDI, Sociodemographic Index.
aUI is the uncertainty interval, which reﬂects the certainty of an estimate based on data availability, study size, and consistency across data sources.
bPercentage attributed to overall rate is the proportion of overall age-standardized rate change attributed by each of the following 4 causes: diabetes, hypertension, glomerulonephritis, and other causes.
cLow SDI: SDI < 0.46; low-middle SDI: 0.46–0.64; middle SDI: 0.65–0.74; high-middle SDI: 0.75–0.85; high SDI: SDI > 0.85.
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was a graded decrease of age-standardized DALY rates of CKD
as SDI quintile increased, in that DALY rates were highest for
the low-SDI quintile (662.45, UI ¼ 738.77–598.73) and
gradually decreased to lowest in the highest SDI quintile
(276.47, UI ¼ 304.94–248.55) (Supplementary Figure S9). To
develop an understanding of the distribution of CKD burden
in relation to countries’ health system performance, we
examined the relationship between age-standardized DALY
rates and HAQ (Figure 5). Results revealed an inverse rela-
tionship, in that countries with high HAQ had relatively lower
age-standardized CKD DALY rates, whereas countries with
low HAQ had much higher CKD age-standardized DALY
rates (r ¼ –0.52). Spline analyses of the relationship between
age-standardized DALY rates and HAQ, which also controlled
for SDI, showed a near linear association (Supplementary
Figure S10A). Because regional differences might confound
the association of HAQ and DALYs, we developed analytic
strategies to examine the relationship after accounting for
GBD regions; the results were consistent in that there was a
near linear inverse relationship between age-standardized
DALY rates and HAQ within GBD regions (Supplementary
Figure S10B). Taken together, the ﬁndings suggest that a
disproportionally higher burden of CKD is borne by coun-
tries that are least equipped to handle it.
In order to gain a better understanding of the potential
improvement in CKD DALY rates that are potentially achiev-
able given a country’s development status, we built a frontier
analysis based on age-standardized DALY rates and SDI using
data from 1990 to 2016 (Figure 6a). The frontier line delineates
the countries and territories with lowest DALY rates (optimal
performers) given their SDI. Distance from the frontier is
termed effective difference and represents the gap between a
country’s observed and potentially achievable DALYs; this gap
could be potentially reduced or eliminated based on the
country or territory’s sociodemographic resources (Table 1).
The effective difference from the frontier for each country and
territory was calculated using the 2016 DALYs and SDI
(Figure 6b and Supplementary Table S4). Overall, the effective
difference for a given SDI tended to be smaller and exhibited
less variance as SDI increased. The top 10 countries with
highest effective difference from the frontier (range of effective
difference: 1829.83–1241.34) included the Solomon Islands,
Fiji, the Federated States of Micronesia, the Marshall Islands,
Afghanistan, El Salvador, Vanuatu, Mauritius, Mexico, and
Nicaragua; these countries have disproportionally higher CKD
DALY rates than other countries with comparable socio-
demographic resources. The top 10 countries with the lowest
DALY rates given their place on the development spectrum and
thus the lowest effective difference (range: 24.01–51.65)
included Finland, Andorra, United Kingdom, Iceland,
Ukraine, Sweden, Norway, France, Moldova, and Slovenia.
DISCUSSION
In this work we show that from 1990 to 2016, the burden of
CKD measured in incidence, prevalence, death due to CKD,
and DALYs due to CKD increased substantially. Globally, inT
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Figure 1 | (a) Worldwide prevalence of chronic kidney disease (CKD). (b) Worldwide age-standardized prevalence rate of CKD. Rate is
per 100,000 population. ATG, Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, Island; LCA, Saint Lucia; TLS, Timor-Leste; TTO,
Trinidad and Tobago; VCT, Saint Vincent and the Grenadines. Heat gradient represents deciles from red (highest) to blue (lowest).
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2016 there were more than 21 million incident cases of CKD
per year (an increase of 88.76%), 276 million prevalent cases
(an increase of 86.95%), nearly 1.2 million deaths due to CKD
(an increase of 98.02%), and 35million years of healthy life lost
due to CKD (an increase of 62.21%). Change in CKD burden
varied by level of development and geography. Decomposition
of CKD DALYs showed that the increase was primarily driven
by population growth and aging, and was tempered (but far
from offset) by decrease in age-standardized mortality and
morbidity rates in most GBD regions except in High-income
North America, Central Latin America, Oceania, Southern
Sub-Saharan Africa, and Central Asia, where the tide of
diabetes and the increased burden of CKD due to diabetes
outpaced burden expected by demographic forces of popula-
tion growth and aging. The results show that the burden is
more disproportionally borne by countries that are least
equipped to handle it, but opportunities for reduction in CKD
burden exist at all levels of development.
There are several cross-cutting themes that are evident in
this analysis. First, the forces of demographic expansion
(population growth and aging) have dramatically inﬂuenced
the change in burden of CKD in each SDI quintile. Second,
the underlying epidemiologic trends (decreased underlying
morbidity and mortality rates due to CKD) have softened
(lessened) but far from offset the impact of population
growth and aging. Third, although there was remarkable
heterogeneity in demographic and epidemiologic trends
across the development spectrum and across GBD regions,
decomposition analyses of CKD burden by cause revealed
substantial variation but a consistent theme of diabetes fol-
lowed by hypertension as leading drivers of CKD. Fourth, the
burden of CKD was more heavily tilted toward poorer and
less well-developed economies, and countries with highest
age-standardized CKD DALY rates had the lowest perfor-
mance on health care access and quality measures. Fifth, our
frontier analysis suggested that even at the low end of the
development spectrum, there are several countries with
leading performance in CKD DALYs; these countries may
serve as exemplars to identify drivers of success, and echo a
theme in many GBD studies that “development is not des-
tiny,” suggesting that a country or territory’s place on the
development spectrum should not preclude it from aligning
policies and leveraging available resources to realize potential
opportunities for reduction in burden of kidney disease.
In this analysis, and according to the GBD data and meth-
odologies, the 2016 prevalence rate of CKD was 3.7%, and
age-standardized prevalence was 4.1%. The estimates may not
be immediately comparable to other studies that have
Figure 3 | Changes in chronic kidney disease (CKD) disability-
adjusted life-years (DALYs) according to population-level
determinants of population growth, aging, and epidemiological
change from 1990 to 2016 at the global level and by
Sociodemographic Index (SDI) quintile. The black dot represents
the overall value of change contributed by all 3 components. For each
component, the magnitude of a positive value indicates a
corresponding increase in CKD DALYs attributed to the component;
the magnitude of a negative value indicates a corresponding
decrease in CKD DALYs attributed to the related component.
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Figure 2 | Chronic kidney disease (CKD) prevalence rate across age groups at the global level and by Sociodemographic Index (SDI)
quintiles. Rate is per 100,000 population.
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exclusively reported prevalence in the adult population.
However, these estimates are generally congruent with ﬁndings
by Brück et al., who reported an adjusted prevalence of CKD
stage 3 to 5 of 1.0% to 5.9% in the European Union.7 Estimates
reported by Mills et al. and Hill et al.8,9 were higher. And es-
timates in other studies exhibited substantial variability10,11;
the variability in estimates by these studies is likely the reﬂec-
tion of several factors, including the methodology of
measuring creatinine, issues related to calibration and esti-
mating equations, the representativeness of the population
Figure 4 | Changes in chronic kidney disease (CKD) disability-
adjusted life-years (DALYs) according to the 4 causes from 1990
to 2016 at the global level and by Sociodemographic Index (SDI)
quintile. The black dot represents the overall value of change
contributed by all 4 causes. For each component, the magnitude of a
positive value indicates a corresponding increase in CKD DALYs
attributed to the component; the magnitude of a negative value
indicates a corresponding decrease in CKD DALYs attributed to the
related component.
Figure 5 | Association between age-standardized chronic kidney
disease (CKD) disability-adjusted life-years (DALY) rate and
Healthcare Access and Quality index. Each circle represents a
country; circles are colored according to Sociodemographic Index
(SDI) quintile; circle size corresponds to population number.Ta
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examined, the age and gender structure of the population
studied, and possibly other explanatory factors.10–26 The GBD
integrative meta-regression approach comprehensively
incorporates all dimensions of health data from different
sources, considers the underlying demographic parameters of
populations, corrects for inconsistencies, and ﬁlls in gaps when
data are incomplete, ultimately producing the GBD
estimates.27 Furthermore, GBD also provides a measure of
uncertainty (uncertainty intervals) to show how much is
known, but perhaps more importantly, how much we do not
know about the burden of a speciﬁc disease in each country. As
such, the estimates provided in this report have integrated data
from all epidemiologic reports and might more closely
approximate the true burden of CKD in any given country.
While the world’s health is improving, as global DALYs from
all diseases fell from 2,448,430,506.75 (UI ¼ 2,305,218,240.22–
2,608,339,531.40) in 1990 to 2,391,258,032.63 (UI ¼
2,184,254,133.63–2,631,699,016.86) in 2016, CKD DALYs have
increased from 21,597,163.60 (UI ¼ 20,093,986.99–
23,354,864.85) in 1990 accounting for 0.88% of all DALYs to
b
a 2015
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-
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Figure 6 | (a) Frontier analysis based on Sociodemographic Index (SDI) and age-standardized chronic kidney disease (CKD) disability-
adjusted life-years (DALY) rate from 1990 to 2016. Color scale represents the years from 1990 depicted in gray to 2016 depicted in green.
The frontier is delineated in solid black color. (b) Frontier analysis based on SDI and age-standardized CKD DALY rate in 2016. The frontier is
delineated in solid black color; countries and territories are represented as dots. The top 15 countries with the largest effective difference
(largest CKD DALYs gap from the frontier) are labeled in black; examples of frontier countries with low SDI (<0.5) and low effective difference
are labeled in blue (e.g., South Sudan, Burundi, Democratic Republic of Congo, Madagascar, Rwanda, and Nigeria), and examples of countries
and territories with high SDI (>0.85) and relatively high effective difference for their level of development are labeled in red (e.g., United States,
Puerto Rico, US Virgin Islands, Brunei, and Taiwan). Red dots indicate an increase in age-standardized CKD DALY rate from 1990 to 2016; blue
dots indicate a decrease in age-standardized CKD DALY rate between 1990 and 2016. DRC, Democratic Republic of Congo.
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35,032,384.43 (UI ¼ 32,622,072.69–37,954,350.03) in 2016,
accounting for 1.47% of all DALYs.28 The increase in burden of
CKD does not only reﬂect a shift from communicable to non-
communicable diseases, but also an increasing share of CKD
DALYs within the noncommunicable disease group, from2.01%
in 1990 to 2.39% in 2016.28,29 Compared with other disease
entities, themagnitude of health loss fromCKD is substantial; for
example, CKDDALYs in 2016 (35,032,384.43) were higher than
DALYs for all digestive diseases (34,368,942.12) and nearly 61%
of DALYs for diabetes (57,233,688.58).28
The number of deaths caused by CKD has nearly doubled,
from 0.6 million deaths in 1990 to 1.2 million deaths in 2016;
CKD was the 18th leading cause of death in 1990 and
ascended to the 11th leading cause of death in 2016.28 From
1990 to 2016, the all-cause age-standardized death rate
decreased, in which death rates decreased for communicable
and noncommunicable diseases.28 However, within the non-
communicable diseases category, rates decreased for cardio-
vascular diseases, cancer, and digestive diseases and increased
for CKD, diabetes, neurologic disorders, and drug use dis-
orders.28 This dramatic divergence in mortality trends is most
likely a reﬂection of progress made in the management of
cardiovascular diseases, cancer, and digestive diseases, and
lack of progress in CKD, diabetes, and neurologic diseases,
and is a manifestation of our overwhelming failure of stem-
ming the tide of death from substance use disorders. Inter-
estingly, and although age-standardized death rates from
CKD due to diabetes and hypertension have increased, death
rates of CKD due to glomerulonephritis have decreased be-
tween 1990 and 2016, which represents a bright spot and il-
lustrates some progress made in the treatment of
glomerulonephritis globally.
The overall increase in burden of CKD is in large part
driven by aging and population growth. The raw incidence,
prevalence, death, and DALYs of CKD have increased; how-
ever, age-standardized incidence and prevalence rates have
not changed appreciably, and the age-standardized death rate
exhibited a tempered increase of 4.39% while its share of
overall death increased signiﬁcantly from 1.45% in 1990
(ranking 14th) to 2.19% in 2016 (ranking 10th). Between
1990 and 2016, age-standardized DALY rates decreased by
4.09%, which represents some progress; however, its share of
all age-standardized DALYs increased from 1.08% in 1990
(ranking 25th) to 1.49% (ranking 21st) in 2016.28
In our analyses, we observed that the increased burden of
CKD is driven in large part by the increased global epidemic of
diabetes and to a lesser extent hypertension.3,4,30 Over the past
27 years, the increased burden of CKDdue to diabetes andCKD
due to hypertension contributed 50.62% and 23.26% of the
increased burden of overall CKD, respectively. The relative
contribution of diabetes as a driver varied by SDI and by GBD
region; overall, the relative contributions of diabetes and
hypertension as drivers of change in DALYs have decreased as
SDIdecreased. Diabetes was responsible formuch of the change
in DALYs in Australasia, East Asia, Southeast Asia,
High-income North America, High-income Asia Paciﬁc, and
Oceania (Supplementary Table S3 and Figure 8b). Whereas
globally and in many GBD regions the underlying morbidity
and mortality rates of CKD have declined, there are several
GBD regions that diverged from this trend and exhibited an
increase in these rates, namely Oceania, Southern Sub-Saharan
Africa, Central Latin America, High-income North America,
and Central Asia. Our decomposition analyses suggest that in
these regions particularly, the epidemic of diabetes and subse-
quently CKD due to diabetes not only outpaced the increased
burden that would be expected by population growth and aging
and but also overwhelmed progressmade to reduce the burden;
CKD due to diabetes is affecting younger members of the
population, and for each age group the rates were higher than
expected based on demographic expansion in several
geographic regions.
In this study, we found that the burden of CKD is more
heavily tilted toward countries with less well-developed
economies; there was also an inverse relationship between
age-standardized DALY rates and measures of health care
access and quality. While this analysis highlights a signiﬁcant
challenge, our frontier analysis provides a more optimistic
assessment in that there are several countries at all levels of
the development spectrum with CKD DALYs that are distant
from the frontier (with relatively large effective difference
from the frontier), which suggests unrealized opportunities
to close the DALYs gap. While frontier countries exist at all
SDI levels, most notable are those with low SDI, which
exhibited leading performance despite constrained re-
sources; these countries might serve as exemplars on opti-
mization of health outcomes in low-resource settings.
Conversely, several countries with high SDI delivered lag-
ging performance (e.g., United States and Taiwan), an
observation suggesting that health progress enabled by
sociodemographic prosperity may be overwhelmed by other
forces. Future work should be undertaken to identify drivers
of success in exemplar countries31 and forces hampering
progress in laggard countries; addressing this knowledge gap
will likely be useful in informing effort to alleviate the
burden of CKD.32,33
As in any assessment of this scope, this study has limitations.
First, this is a macro-level assessment of global, regional, and
national epidemiologic trends of CKD over the span of more
than a quarter century, and as such it may not have captured
micro level trends.31 This may be especially relevant in large
geographies (e.g., China, India, and the United States), which
may exhibit signiﬁcant subnational variation in burden of CKD
not reﬂected in our analyses.7–10,15 We relied on the GBD data
to produce the estimates provided in this report, and while
GBD methodologies and results are considered state-of-the-
art, robust, and reliable, they are necessarily limited by the
quality of the available data.27 For many countries with limited
data, GBD estimates were derived bymathematicalmodeling.27
Furthermore, variability and inconsistency of data collection
methods and tools across the countries and over time could
inﬂuence geographic variations and temporal trends.34 In this
analysis, we did not report burden of CKD by gender, and we
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did not restrict the analyses to the adult population. Our
decomposition analyses consideredmajor demographic factors
and the 4 causes of CKD as deﬁned by the GBD framework;
other potential drivers likely exist but are beyond the scope of
this analysis. While we outlined several limitations, we, how-
ever, note that because the GBD estimates will be updated
annually, we anticipate that data collection systems and GBD
methodologies will continue to evolve to address some of these
limitations (e.g., provision of subnational estimates). Key
strengths include leveraging the availability of the GBD data
spanning the years 1990 to 2016; the GBD data is the most
comprehensive compilation and analysis of global health in-
formation available. We developed decomposition analyses to
elucidate the inﬂuence of demographic trends and cause of
disease as drivers of change in burden of CKD over the past 27
years, and ﬁnally, we developed a frontier analysis to enable
comparative evaluation among countries with similar SDI.
In conclusion, the global toll of CKD is substantial and has
risen dramatically over the past 27 years; death and disability
due to CKD have increased, largely driven by population
growth and aging. Diabetes followed by hypertension were
the leading drivers of CKD globally. There was a signiﬁcant
variation in demographic and epidemiologic trends among
geographic regions, and the burden of CKD is more heavily
tilted toward less well-developed economies with suboptimal
health system performance. While health loss due to CKD
exhibited a relationship with measures of economic and
sociodemographic prosperity, our frontier analysis showed
that “development is not destiny,” as several countries with
constrained resources have a leading performance for CKD
DALYs and may serve as exemplars to others to help reduce
suffering from kidney disease. The rising burden of CKD
should be reﬂected in the global and national health agendas.
MATERIALS AND METHODS
Data sources
The GBD study provides a detailed epidemiologic assessment of 333
diseases and injuries and 84 risk factors by age and sex on a global scale
and for 195 countries and territories spanning the years from 1990 to
2016.37–44 An integrative Bayesian meta-regression method that esti-
mates a generalized negative binomialmodel for all epidemiological data
was used throughDisMod-MR2.1 in the computation ofGBDestimates
of disease burden27; detailed descriptions of overall GBD 2016 meth-
odologies and speciﬁc CKD methodology have been provided else-
where.27,35–39 Data on CKD incidence, prevalence, death due to CKD,
and DALYs and their uncertainty intervals were curated fromGBD data
sources. All GBD data used in this study were obtained from the Global
Burden of Disease Collaborative Network; results were provided by the
Institute for Health Metrics and Evaluation (Seattle, WA).28
In the GBD study, CKD was considered both as a disease and a
metabolic risk factor. In this analysis, we approached CKD as a
disease. CKD was deﬁned as estimated glomerular ﬁltration rate of
less than 60 ml/min per 1.73 m2.36
Measures of burden
Measures of burden at the global, regional, and national levels
included incidence, prevalence, death due to CKD, and DALYs due to
CKD (Table 1). Death due to CKD was estimated by the GBD using
cause of death ensemble model.38,43 DALYs were calculated through
summation of years livedwith disability and years of life lost. The years
lived with disability is a measure of disease burden that represents the
years lived with CKD; it considers the duration of time living with the
disease and related disability weights to reﬂect the underlying severity
of CKD. The years of life lost represented the years lost due to pre-
mature mortality caused by CKD. Both years lived with disability and
years of life lost were estimated for each age, gender, and location in a
speciﬁc year (Table 1). All measures are reported as raw values, rates
per 100,000 population, and age-standardized rates per 100,000
population, where age standardization was based on theWorld Health
Organization world population standard age structure.
Country classiﬁcation
In our analyses we classiﬁed countries according to the 2016 SDI in
quintiles (Table 1). SDI is a standardized composite summarymeasure
on a scale of 0 to 1 that is comparable by geography and over time44; it
includes (i) average income per person, (ii) educational attainment,
and (iii) total fertility rate of the country. We also classiﬁed countries
according to GBD region, and according to World Bank Income
Group in ﬁscal year 2018 (Supplementary Table S1).
Decomposition analysis
To gain a better understanding of explanatory factors that drove change
in CKD DALYs between 1990 and 2016, we conducted decomposition
analyses by (i) population size, age structure, and epidemiologic
changes, and (ii) CKD cause. The decomposition analyses (further
deﬁned in Table 1 and described in detail in Supplementary Methods)
show the change in CKD DALYs contributed by each component.
Health Care Access and Quality
The HAQ index provides a summary measure on a scale of 0 to 100 to
facilitate comparison of personal health care access and quality by
geography and over time44 (Table 1). To gain a better understanding of
the distribution of CKD burden in relation to countries’ health system
performance, we examined the relationship between age-standardized
DALY rates in 2016 and HAQ in 2015 by Pearson correlation coefﬁ-
cient. Further details are provided in Supplementary Methods.
Frontier Analysis
To evaluate the relationship between burden of CKD and socio-
demographic development, we applied a frontier analysis as a
quantitative methodology to identify the lowest potentially achiev-
able age-standardized DALY rate on the basis of development status
as measured by the SDI (Table 1). The methodology of the frontier
analysis is further described in Supplementary Methods.
Statistical software SAS Enterprise Guide 7.1 was used for the
analyses. Maps were generated using ArcGIS 10.5.1 developed by
ESRI (Redlands, CA).
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Supplementary Methods.
Table S1. Classiﬁcation of countries according to Global Burden of
Disease (GBD) region, Sociodemographic Index (SDI) quintile, and
World Bank income.
Table S2A. Number, rate, and age-standardized rate for overall
chronic kidney disease (CKD) incidence and by cause of CKD in 2016
and percentage change from 1990.
Table S2B. Number, rate, and age-standardized rate for overall
chronic kidney disease (CKD) prevalence and by cause of CKD in 2016
and percentage change from 1990.
Table S2C. Number, rate, and age-standardized rate for overall
chronic kidney disease (CKD) death and by cause of CKD in 2016 and
percentage change from 1990.
Table S2D. Number, rate, and age-standardized rate for overall
chronic kidney disease (CKD) disability-adjusted life-years (DALYs)
and by cause of CKD in 2016 and percentage change from 1990.
Table S3. Changes in disability-adjusted life-years (DALYs) according
to population-level determinants and causes from 1990 to 2016.
Table S4. Frontier disability-adjusted life-years (DALYs) and effective
difference by country or territory.
Figure S1. (A) Global chronic kidney disease (CKD) incident number,
rate, and age-standardized rate from 1990 to 2016. (B) Global age-
standardized incident rate of CKD by 4 causes from 1990 to 2016.
Rate per 100,000 population.
Figure S2. (A) Global chronic kidney disease (CKD) prevalence
number, rate, and age-standardized rate from 1990 to 2016. (B)
Global age-standardized prevalence rate of CKD by 4 causes from
1990 to 2016. Rate per 100,000 population.
Figure S3. (A) Global death number, rate, and age-standardized rate
due to chronic kidney disease (CKD) from 1990 to 2016. (B) Global
age-standardized death rate due to CKD by 4 causes from 1990 to
2016. Rate per 100,000 population.
Figure S4. (A) Global chronic kidney disease (CKD) disability-adjusted
life-years (DALYs) number, rate, and age-standardized rate from 1990
to 2016. (B) Global age-standardized CKD DALY rate by 4 causes from
1990 to 2016. Rate per 100,000 population.
Figure S5. (A) Proportion of chronic kidney disease (CKD) prevalence
in each age group at the global level and by Sociodemographic Index
(SDI) quintile. (B) Proportion of death due to CKD in each age group
at the global level and by SDI quintile.
Figure S6. (A) Population-level determinants attributed to changes in
chronic kidney disease (CKD) disability-adjusted life-years (DALYs)
from 1990 to 2016 at the global level and by Sociodemographic Index
(SDI) quintile. (B) Changes in CKD DALYs according to population-
level determinants from 1990 to 2016 by Global Burden of Disease
(GBD) region.
Figure S7. Changes in chronic kidney disease (CKD) disability-
adjusted life-years (DALYs) number by CKD cause and age group from
1990 to 2016 after accounting for contribution of population growth
and aging. Causes included diabetes, hypertension, glomerulone-
phritis, and other causes from 1990 to 2016. Analyses were performed
in Global Burden of Disease (GBD) regions that exhibited an increase
in age- and population-standardized CKD DALY rates, including high-
income North America, Oceania, Central Latin America, Central Asia,
and Southern Sub-Saharan Africa.
Figure S8. (A) Four causes attributed to changes in chronic kidney
disease (CKD) disability-adjusted life-years (DALYs) from 1990 to 2016
by Sociodemographic Index (SDI) quintile. (B) Changes in CKD DALYs
according to 4 causes from 1990 to 2016 by Global Burden of Disease
(GBD) region.
Figure S9. Age-standardized chronic kidney disease (CKD) disability-
adjusted life-years (DALY) rate by World Bank Income classiﬁcation
and Sociodemographic Index (SDI) quintile.
Figure S10. (A) Spline analysis for association between Healthcare
Access and Quality (HAQ) and age-standardized chronic kidney disease
(CKD) disability-adjusted life-years (DALY) rate. (B) Spline analysis for
within-regionassociationbetweenHealthcareAccess andQuality (HAQ)
and age-standardized CKD DALY rate. Rate per 100,000 population.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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